EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Checkpoint Inhibitor Pneumonitis: Updates in Management

Myah McCrary, Muhammad Ahsan, Chaofan Yuan, Alpa G. Desai, Department and institution

Medical Research Archives · 05.09.2025 · 13 (7)

DOI: 10.18103/mra.v13i7.6740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 05.09.2025. Verfasst von Myah McCrary und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening immune-related adverse event associated with immune checkpoint inhibitors (ICIs). While high-dose corticosteroids remain the first-line treatment, up to 40% of patients experience steroid-refractory or resistant disease, posing significant management challenges. This review synthesizes current evidence on evolving CIP management strategies, highlighting both established therapies and emerging options. Recent guidelines favor mycophenolate mofetil (MMF) and intravenous immunoglobulin (IVIG) as second-line agents, replacing infliximab due to infection concerns in this immunocompromised population. Additional therapies such as cyclophosphamide, calcineurin inhibitors, and pulsed-dose corticosteroids have shown benefit in select cases, though evidence remains limited. Advances in understanding CIP immunopathogenesis have spurred interest in targeted biologics, notably interleukin-6 inhibitors like tocilizumab, which demonstrate promise in early reports. Antifibrotic agents, including nintedanib and pirfenidone, are also under investigation for their potential to manage fibrosis, particularly in patients with underlying interstitial lung disease or progressive fibrotic changes. Experimental strategies such as plasmapheresis, granulocyte-macrophage colony-stimulating factor (GM-CSF) modulation, and Janus kinase (JAK) inhibitors are being explored, with several prospective trials underway. Despite these advances, challenges persist in early diagnosis, risk stratification, and the absence of prospective, biomarker-driven treatment algorithms. This review emphasizes the importance of multidisciplinary, individualized management and highlights promising avenues for future research to improve outcomes in this increasingly encountered complication of cancer immunotherapy.

Zitieren

APA

McCrary, M., Ahsan, M., Yuan, C., Desai, A. G., & institution, D. A. (2025). Checkpoint Inhibitor Pneumonitis: Updates in Management. Medical Research Archives, 13(7). https://doi.org/10.18103/mra.v13i7.6740

Vancouver

McCrary M, Ahsan M, Yuan C, Desai AG, institution DA. Checkpoint Inhibitor Pneumonitis: Updates in Management. Medical Research Archives. 2025;13(7). doi:10.18103/mra.v13i7.6740

BibTeX
@article{McCrary2025,
  author = {McCrary, Myah and Ahsan, Muhammad and Yuan, Chaofan and Desai, Alpa G. and institution, Department and},
  title = {Checkpoint Inhibitor Pneumonitis: Updates in Management},
  journal = {Medical Research Archives},
  year = {2025},
  volume = {13},
  number = {7},
  doi = {10.18103/mra.v13i7.6740}
}
Kostenlos starten →